{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:19:42Z","timestamp":1784560782465,"version":"3.55.0"},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Although hemorrhagic cystitis (HC) is a significant complication in young patients who undergo chemotherapy with cyclophosphamide (CPA), risk factors and supportive care to prevent HC are unclear. This study attempted to identify optimal supportive care to prevent CPA\u2010induced HC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients (&lt;\u00a030\u2010year\u2010old) with malignant solid tumors who had been treated with CPA\u2010containing chemotherapy in inpatient treatment were eligible. Vigorous hydration to increase urine output and intravenous 2\u2010mercaptethane sulfonate (mesna) were used for prophylaxis of CPA\u2010induced HC. We retrospectively analyzed 81 patients who had been treated with CPA\u2010containing chemotherapy over (collectively) 486 cycles, and examined relationships between HC and various factors, especially CPA dosage, use of mesna, and fluid infusion volume\/rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HC occurred in four patients (4.9%) and five cycles (1%). When stratifying by doses and methods of administration of CPA, HC occurred in 3\/323 low\u2010 and intermediate\u2010dose (&lt;\u00a01500\u00a0mg\/m<jats:sup>2<\/jats:sup>\/day) cycles and mesna was used in all three cycles with HC. Patients who were given mesna had a lower flow rate than those given hydration alone in the low\u2010 and intermediate\u2010dose CPA (126 \u00b1 25<jats:italic>vs<\/jats:italic>106 \u00b1 16\u00a0mL\/m<jats:sup>2<\/jats:sup>\/h;<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.01). All patients who received high\u2010dose CPA (\u22651500\u00a0mg\/m<jats:sup>2<\/jats:sup>\/day) were also given mesna and vigorous hydration (115 \u00b1 16\u00a0mL\/m<jats:sup>2<\/jats:sup>\/h).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our supportive care measures may be effective in preventing CPA\u2010induced HC. Patients who receive CPA doses\u00a0&lt;\u00a01500\u00a0mg\/m<jats:sup>2<\/jats:sup>\/day should get \u2265125\u00a0mL\/m<jats:sup>2<\/jats:sup>\/h of infused fluid, regardless of mesna usage; those who receive of CPA \u22651500\u00a0mg\/m<jats:sup>2<\/jats:sup>\/day should also receive mesna and vigorous hydration.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13048","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T10:01:03Z","timestamp":1531216863000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cyclophosphamide\u2010induced hemorrhagic cystitis in young patients with solid tumors: A single institution study"],"prefix":"10.1111","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2476-2862","authenticated-orcid":false,"given":"Yoshimasa","family":"Saito","sequence":"first","affiliation":[{"name":"Department of Pharmacy National Cancer Center Hospital Tokyo Japan"},{"name":"Faculty of Pharmaceutical Sciences Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University Kanazawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Kumamoto","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Shiraiwa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Sonoda","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikumi","family":"Tamai","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University Kanazawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitose","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Terakado","sequence":"additional","affiliation":[{"name":"Department of Pharmacy National Cancer Center Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500157"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0090-9556(24)15302-0","article-title":"Development of a substrate\u2010activity based approach to identify the major human liver P\u2010450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA\u2010expressed activities and liver microsomal P\u2010450 profiles","volume":"27","author":"Roy P","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0590-6"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(79)90222-3"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-006-0078-0"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00410691"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3333"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.1.76"},{"key":"e_1_2_7_10_1","volume-title":"Supportive Care of Children with Cancer","author":"Children's Oncology Group","year":"2004"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000063640.41307.c9"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2007.00705.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.08.007"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(82)90633-1"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198710223171717"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880201)61:3<451::AID-CNCR2820610308>3.0.CO;2-G"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyw093"},{"key":"e_1_2_7_19_1","first-page":"226","article-title":"Clinical pharmacology of cyclophosphamide","volume":"33","author":"Bagley CM","year":"1973","journal-title":"Cancer Res"},{"key":"e_1_2_7_20_1","first-page":"451","article-title":"Studies on the human pharmacokinetics of isophosphamide (NSC\u2010109724)","volume":"60","author":"Allen LM","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_7_21_1","first-page":"2313","article-title":"Similar bioavailability of single\u2010dose oral and intravenous mesna in the blood and urine of healthy human subjects","volume":"4","author":"Goren MP","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.11.2016"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000012062"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2627"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.13048","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T17:42:55Z","timestamp":1751737375000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/ajco.13048"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13048","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"assertion":[{"value":"2018-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}